GLP-1 receptor agonist prescription trends 2012-2023
Diabetes Obes Metab 20(3):479487 Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, VADT Investigators et al (2015) Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
10.1056/NEJMoa050373 [DOI] [PubMed] [Google Scholar] 327.Lee, M.-H
These include addressing resistance mechanisms, optimizing EMF parameters (for example, determining the appropriate ELF frequency and intensity for safe ferroptosis induction, as well as the proper terahertz dosing to avoid unwanted inhibition), and validating combinations with SAFETY CONSIDERATIONS Although emerging studies highlight the therapeutic potential of EMFbased interventions, their safety profile requires careful consideration, particularly regarding normal tissue toxicity and potential carcinogenic risks from chronic exposure